ArticleScientific reports2026
Targeting oxidative stress and mitochondrial dysfunction via URG7 overexpression in an in vitro Parkinson's disease neuronal model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neurodegenerative diseases represent a major healthcare challenge for aging populations, characterized by the progressive decline of neuronal function and subsequent brain atrophy. Despite differences in the brain regions affected and the underlying causes, these pathologies share common cellular and molecular mechanisms, including oxidative stress and mitochondrial dysfunction. Among neurodegenerative disorders, Parkinson’s disease (PD) is particularly associated with oxidative stress–driven dopaminergic neurodegeneration, in which reactive oxygen species (ROS) play a crucial role by contributing to cellular damage and neuronal death. This study investigates the role of Up-Regulated Gene 7 (URG7), a protein localized in the endoplasmic reticulum, in modulating oxidative stress in genetically engineered SH-SY5Y neuroblastoma cells overexpressing URG7, exposed to 6-hydroxydopamine (6-OHDA), a neurotoxin used as a Parkinson’s disease mimetic. We hypothesized that URG7 overexpression mechanistically modulates oxidative stress responses and mitochondrial integrity in neuronal cells subjected to Parkinson’s disease–related oxidative insult. Our results demonstrate that URG7 significantly reduces cell death and oxidative stress by enhancing cellular antioxidant defenses. Specifically, URG7 upregulates key antioxidant enzymes, including catalase and superoxide dismutase 2, and activates the Nrf2 signaling pathway, crucial for cellular detoxification. Furthermore, URG7 preserves mitochondrial membrane potential and regulates the expression of proteins involved in mitochondrial quality control, such as PINK1, Parkin, and DJ-1. Overall, these findings suggest that URG7 acts as a protective sentinel against oxidative stress and mitochondrial dysfunction, highlighting its potential as a therapeutic target for neurodegenerative diseases, particularly Parkinson’s disease. Further investigation into the molecular mechanisms of URG7, building on the biological evidence provided here, could pave the way for new neuroprotective strategies aimed at counteracting oxidative damage and promoting neuronal survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.